Across TCGA pan-cancer cohorts, IGLV3-9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGLV3-9 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGLV3-9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV3-9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

UCEC, HNSC, and CCRCC are the cancer types where IGLV3-9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.424	1.000	.003	48	view →
HNSC	DFS	Tertile	III,IV	0.771	0.341	<.001	46	view →
CCRCC	DFS	Quartile	III,IV	0.864	0.356	<.001	19	view →
LUAD	OS	Quartile	All	0.910	1.000	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGLV3-9 tumor-vs-normal RNA expression · all IGLV3-9 data types